INN talks with the management team members from BELLUS Health, Immune Pharmaceuticals IntelGenX, and Sierra Oncology.
During the recent Biotech Showcase conference in San Francisco, the Investing News Network (INN) had the opportunity to talk with a variety of CEO’s on the development of their companies and where they are heading to next.
Here’s a quick look at the companies we talked to and their respective representative:
Roberto Bellini, president, and CEO of BELLUS Health (TSX:BLU). This company is a biopharmaceutical working on the development of their lead candidate, BLU-5937 which is meant to treat chronic coughing. Bellini told INN about how the company worked on the development of their drug with patients in mind and by looking at the flaws from their competitors.
BELLUS is starting a difficult process for all life science companies, the preparation for the phase 2 stage of their trial. Bellini talked about the plans for the company to remain relevant while it engages in this type of preparation work.
Elliot Maza is the president and CEO of Immune Pharmaceuticals (NASDAQ:IMNP) a company developing candidates against immunologic and inflammatory diseases. The company recently decided to spin off their immuno-oncology into another company, which according to Maza was decided to do because the board of directors wanted to refocus on their core business.
Maza announced the company made a special round of financing that will be able to carry their company to complete their goals this year.
Horst Zerbe is the president and CEO of IntelGenX (TSXV:IGX; OTCQX:IGXT), a drug company focused on the oral drug delivery technique. Their pipeline hosts a variety of candidates with several in the mid to last stages of development. One of their more interesting products is made in a partnership with Tetra Bio-Pharma (TSXV:TBP), a cannabis medical company in Canada. This candidate, Dronabinol AdVersa, is set to treat pain management.
Nick Glover president and CEO of Sierra Oncology (NASDAQ:SRRA) told INN about the company’s unique position in the drug development sector with their DNA Damage Response (DDR) therapeutics. Glover told INN about whether he is noticing I/O fatigue taking place in the industry at large.
Don’t forget to follow @INN_LifeScience for real-time updates!
Editor’s Note: This story was updated to correct the market Sierra Oncology is focused on.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.